Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

Using Direct Non-thermal Atmospheric Pressure Plasma With Penetration Enhancement for the Treatment of Hair Loss

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06149221

Enrollment

Registered

2023-11-28

Start date

2023-09-01

Completion date

2024-04-12

Last updated

2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic Alopecia

Brief summary

In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp

Interventions

DEVICENTAP

Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of mild-to moderate androgenetic alopecia * ability to keep in-person follow-up appointments

Exclusion criteria

* any inflammatory scalp condition * starting or discontinuing any hair loss treatments within 6 months of start date * allergy to any components of the carrier solution

Design outcomes

Primary

Measure	Time frame	Description
Presence of detectable hair growth	3 months and 6 months	Presence of hair growth as measured using the HairMetrix device

Secondary

Measure	Time frame	Description
Adverse effects related to the treatment	throughout study completeion, 6 months	Patients are monitored for adverse effects, including but not limited to irritation, itch, inflammation, scaling, redness, rash, peeling, blistering

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026